RAYONEX Schwingungstechnik GmbHSauerland-Pyramiden 1 • D-57368 Lennestadt

Phone: +49 2721/6006-0 • Fax: +49 2721/6006-66

CASE STUDIESACCORDING TO DR. MED. GERHARD BREIER

COLOGNE

Rayocomp PS 1000 polarHigh efficiency bio resonator

Case study on the RAYOCOMP PS 1000© Dr. med. Gerhard Breier, Cologne, October 1993

In an examination- and study-programme the RAYOCOMP PS 1000 was incorporated withthe question, if subtle oscillation therapy methods using resonance frequencies have ahealing impact on pathological changes. For this reason the following sectors with indicationsand case numbers were included in the therapeutical concept:( N = number of patients)

Dermatology N = 35Neurodermatitis N = 20Allergic eczema N = 10Acne N = 5

Orthopedics N = 215Coxarthrosis N = 30Lumbalgia N = 40Spondylarthrocace N = 20Occipital-Neuralgia N = 30Migraine N = 20Ischialgia N = 30Cervical spine syndrome N = 40Distorsion of ankle joint N = 5

Cancer (NPL) N = 2Osteosarcoma N = 1Alveolar-pavement ephitelium N = 1

(Only the serological immune profile was examined in the after-treatment)

Neurology N = 3Amyotrophic lateral sclerosis (ASL) N = 1Extrapyramidal syndrome (EPS) N = 1Guillain-Barre-syndrome (GBS) N = 1

Urology N = 20Cystitis N = 15Pyelitis N = 5

HNO N = 31Sinusitis. N = 20Traumatic laryngitis N = 1Bacterial laryngitis N = 5Otitis media N = 5

Rheumatology N = 21Chronic polyarthritis cP. N = 8Chronic arthrosis N = 13

Circulatory disturbance N = 27Coronary heart diseases CHD N = 5AVK IIb N = 2Ulcus venosum N = 5Cerebral circulatory disturbance N = 15

Psychiatry N = 42Depression, generally N = 12Phobia, generally N = 10Disturbed sleep, generally N = 20

Gastro-enterology N = 56Gastritis N = 20Obstipation N = 20Acute diarrhea N = 4Colitis ulcerosa N = 12

Ophthalmology N = 10Retinal circulatory disturbance N = 8Degenerative process of the macula N = 2

Pulmology N = 52Bronchial asthma N = 20Allergic asthma N = 10Rhinitis allergica N = 22

Altogether 514 patients were treated during this case study.

Every patient had been informed about the effects of the Rayocomp. Some patients wereintentionally given incomplete information to maintain the characteristics of a ”blindexperiment”. Side effects or intolerabilities did not occur in any of the cases. None of thetreatments had to be cancelled.

Between the sessions the patients were given an oral drug on a neutral carrier*1) containingthe same bio-resonance frequencies as the treatment. This led usually to a stabilization of thetherapeutical result. Interestingly enough an improvement of the state of illness was alsoascertainable if the patients were only given the drug and not treated with frequencies. Thedaily dose varied from 1 x 5 drops to 2 x 10 drops. Overdoses almost regularly led tooverreactions including symptoms of hyperactivity.

The therapy was performed with therapy cards or an indicated, unsorted combination ofcards with up to 480 frequencies. The treatment took place two times a week with normally12 applications. Only in case of artrioventricular disease the therapy had to be cancelledbecause of increasing pain, but not until after the 18th application, therefore out of theassesment. In the beginning the treatment was performed with indicated cards, respectivelyonly one card.

*1) A radionic drug is a stimulans, consisting only of energetic potentials and not of material pharmacological substances.

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Therapeutical results (Part 1)© Dr. med. Breier, Cologne, October 1993

Neurodermatitis

Allergic eczema

Acne

Coxarthrosis

Lumbalgia

Spondylarthrocace

Occipital neuralgia

Migraine

Ischialgia

Distorsion of

ankle jointCervical spine syndrome

Speech

Swallowing

Pyramidal-syndrome

GBS

Cystitis

Pyelitis

Frontal sinusitis

Traumatic laryngitis

Bacterial laryngitis

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Therapeutical results (Part 2)© Dr. med. Breier, Cologne, October 1993

Otitis - media

Angina

Chronic polarthritis

Chronic arthrosis

CHD

AVD

Ulcus venosum

Cerebral circulatorydisturbance

Depressions

Phobia

Disturbed sleep

Gastritis

Obstipation

Diarrhea

Colitis ulcerosa

Retinale circulatorydisturbance

Degeneration

of the maculaBronchial asthma

Allergic asthma

Rhinititis allergica

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

First reaction

RecuperationDeterioration

small success

Placebo

Course of treatm

ent (Table 1)

© D

r. med

. Breier, C

ologne, Octob

er 1993

12

34

56

78

910

Neurod

ermatitisA

cne

Allergic eczem

a

Days

Neuro

derm

atitis, therapy card

s: 51 - 5 - 7.A

dditionally from 5th treatm

ent on 15 - 17- 31 - 32 - 34.

Acne, therap

y cards: 51 - 5 - 7- 32.

Additionally from

5th treatment on 29 - 34 - 14 - 15.

Allerg

ic eczema, therap

y cards: 51 - 5 - 7 -15 -17.

Additionally from

5th treatment on 29 -14 - 32 - 34.

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

First reaction

RecuperationDeterioration

small success

Placebo

Course of treatm

ent (Table 2)

© D

r. med

. Breier, C

ologne, Octob

er 1993

12

34

56

78

910

Sp

ondylarthrocace

Lumb

algia

Coxarthrosis

Days

Occip

ital-Neuralgia

Occip

ital-Neuralg

ia, therapy card

s: 51 - 47 - 48.

Additionally from

4th treatment on 1 - 13 - 21 - 46.

Sp

ond

ylarthrocace, therap

y cards: 51 - 36 - 50.

Additionally from

3rd treatment on 46 - 21 -13 - 2.

Lumb

algia, therap

y cards: 51 - 36 - 44 - 37.

Additionally from

7th treatment on 21 - 50 - 48 - 13.

Co

xarthrosis, therap

y cards: 51 - 44 - 37 - 46.

Additionally from

7th treatment on 50 - 15 - 5.

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Cervical sp

ine syndrom

e

Ischialgia

Distorsion of the ankle joint

Days

Migraine

Mig

raine, therapy card

s: 51 - 48 - 50 - 47.A

dditionally from 3rd trearm

ent on 2 - 13 - 21 - 26or 27 - 2 - 3 - 8.

Cervical sp

ine syndro

me, therap

y cards: 51 - 46 - 47 - 48.

Additionally from

3rd trearment on 41 - 50 - 36.

Ischialgia, therap

y cards: 51 - 36 - 50 - 21.

Additionally from

5th trearment on 13 - 44 - 37 - 46.

Disto

rsion o

f the ankle joint, therap

y cards: 38 -37.

Additionally from

7th trearment on 44 - 2 -3.

Course of treatm

ent (Table 3)

© D

r. med

. Breier, C

ologne, Octob

er 1993

12

34

56

78

910

Days

Cystitis, therap

y cards: 28 - 34.

Additionally from

6th treatment on 5 - 14 - 26 or 27.

Pyelitis, therap

y cards:: 34 - 28.

Additionally from

7th treatment on 26 or 27 - 14 - 2 - 3 - 17 - 15

Course of treatm

ent (Table 4)

© D

r. med

. Breier, C

ologne, Octob

er 199390 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

12

34

56

78

910

Pyelitis

Cystitis

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Course of treatm

ent (Table 5)

© D

r. med

. Breier, C

ologne, Octob

er 1993

12

34

56

78

910 chronic

arthrosis

Days

Chronic

polyarthritis

Chro

nic po

lyarthritis cP., therapy card

s: 51 - 50 - 34 - 21.A

dditionally from 5th treatm

ent on 43 - 42 - 45 - 44 - 37.A

dditionally from 7th treatm

ent on 5 - 15 - 17 - 34 - 31 - 30 - 32 - 20.

Chro

nic arthrosis, therap

y cards: 51 - 45 - 37 - 34.

Additionally from

5th treatment on 15 - 17 - 36 - 21 - 5.

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Course of treatm

ent (Table 6)

© D

r. med

. Breier, C

ologne, Octob

er 1993

12

34

56

78

910

Degenerative

process of

the macula

Days

Retinal

circulatoryd

isturbance

Retinal circulatory disturbance, therapy cards: 51 - 11 - 5.

Additionally from 3rd treatm

ent on 3 - 4 - 12 - 14.

Degenerative process of the m

acula, therapy cards same com

bination as above.

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Course of treatm

ent (Table 7)

© D

r. med

. Breier, C

ologne, Octob

er 1993

12

34

56

78

910 P

hobiaD

ays

Dep

ressions

Disturb

edsleep

Disturb

ed sleep

, therapy card

s: 51 - 12 - 13.A

dditionally after 1st treatment 20 - 21.

Additionally from

5th treatment on 11 - 1 - 50 - 15 - 14 - 23.

Dep

ressions, therap

y cards: 51 - 1 - 12 - 13.

Additionally after 3rd treatm

ent 50 - 20.A

dditionally after 4th treatment 26 oder 27 - 3 - 4 - 2.

Pho

bia, therap

y cards: sam

e combination as w

ith depressions

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Course of treatm

ent (Table 8)

© D

r. med

. Breier, C

ologne, Octob

er 1993

12

34

56

78

910

Rhinititis allergicaD

ays

Allergis asthm

a

Bronchial

asthma

Allerg

ic asthma, therap

y cards: 51 - 19.

Ad

ditionally from

2nd treatm

ent on 10 - 20.A

dd

itionally from 4th treatm

ent on12 - 15 - 17 - 32 - 34.

Bro

nchial asthma, therap

y cards: 51 -19.

Ad

ditionally after 1st treatm

ent 20 - 34 - 12.A

dd

itionally after 5th treatment 10 - 17 - 32.

Ad

ditionally after 6th treatm

ent 46 - 23 - 39 - 35.A

dd

itionally after 8th treatment 16 - 30.

Rhinititis allerg

ica, therapy card

s: 51 - 10.A

dd

itionally from 2nd

treatment on 13 - 14.

Ad

ditionally from

6th treatment onh 20 - 34 - 15 -17 - 19.

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Course of treatm

ent (Table 9)

© D

r. med

. Breier, C

ologne, Octob

er 1993

12

34

56

78

910 C

erebral

circulatoryd

isturbance

Days

Coronary

heartd

iseases

Ulcus

venosum

AV

K II b

CH

D, therap

y cards: 51 - 35 - 3 - 4.

Additionally from

5th treatment on 39 - 46

Additionally from

7th treatment on 23 - 16 - 30 - 32 - 50

Ulcus veno

sum, therap

y cards: 3 - 14 -15 -17 - 34.

Additionally from

2nd treatment on 5 - 7 - 14 - 45.

Cereb

ral circ. disturb

., therapy card

s: 51 - 1 - 3 - 4 - 8 - 12.A

dditionally from 4th treatm

ent on 13 - 48 - 47.

AV

K, therap

y cards: 3 - 4 - 44.

Additionally from

4th treatment on 14 - 15.

Additionally from

7th treatment on 35 - 5.

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Course of treatm

ent (Table 10)

© D

r. med

. Breier, C

ologne, Octob

er 1993

12

34

56

78

910 D

iarrheaDays

Ob

stipation

Colitis

ulcerosa

Gastritis

Gastritis, therap

y cards: 51 - 29.

Additionally from

2nd treatment on 30 - 31.

Additionally from

5th treatment on 23 - 18 - 2.

Diarrhea, therap

y cards: 51 - 32.

Additionally from

2nd treatment on 31 - 30 - 29 - 16 - 5 - 17.

Ob

stipatio

n, therapy card

s: 51 - 32.A

dditionally from 3rd treatm

ent on33 - 31 - 30.A

dditionally from 5th treatm

ent on 15 - 17 - 50.

Co

litis ulcerosa, therap

y cards: 51 - 32.

Additionally after 3rd treatm

ent 31 - 30.A

dditionally after 5th treatment 5 - 2 - 16.

Additionally after 9th treatm

ent 14 - 15.

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Course of treatm

ent (Table 11)

© D

r. med

. Breier, C

ologne, Octob

er 1993

12

34

56

78

910

Traum. laryngitis

after intubation

Days

Otitis m

edia

Bact. laryngitis

Sinusitis

Angina

Ang

ina, therapy card

s: 51 - 14.A

dditionally after 1st treatment 9 - 10 - 47 - 15 - 17 - 34 - 5.

Laryngitis, therap

y cards: 9 - 14.

Additionally after 3rd treatm

ent 5 - 3 - 4 - 15.

Otitis m

edia, therap

y cards: 51 - 8.

Additionally after 4th treatm

ent 14 - 10 - 13 - 3 - 4 - 48.

Imm

une status before and

after theR

ayocomp

treatment (Tab

le 1)©

Dr. m

ed. B

reier, Cologne, O

ctober 1993

2300

50004,3

4,841

37

233

18137

52

142

12583

66

84

41

Leucocytes

Evy

HK

Chol.

HD

L

LDL

Triyl.Lip

ase

before

after

Imm

une status before and

after theR

ayocomp

treatment (Tab

le 2)©

Dr. m

ed. B

reier, Cologne, O

ctober 1993

before

after

201000

245000

650

1140

220

350

3,4

2,9

530

850

30

70

110110

330

550

240

47060

30

70

130

Throbo-

cyres

Lymp

ho-cytes

Mono-

cytes

Granulo-

cytes

T-LyB

-Ly

Active

T-cells

T 4

T 8

NK

-cells

cyticT-cells

Here the subpopulation of lym

phocytes before and after 10 treatments w

ith the Rayocom

p was m

easured. With ephiteliom

a after lopektomie

recurrenct. General condition very good. N

o postoperative pain, vital capacity. NA

D. O

f special meaning is the increase of T4 cells from

330to 550 and of T8 cells from

240 to 470, and the imm

une competent N

K-cells increase from

60 to 130 and the cytotoxic cells, that areim

portant for the specific imm

une response, from 30 to 70. This sm

all amount of case num

bers is only useful for observation. There are furtherC

A.-patients in the therapy, but still w

ithout measurable results.

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Efficien

cy with

"N" p

erson

s examin

ed (Tab

le 1)

© D

r. med

. Breier, C

ologne, Octob

er 1993

Neurod

ermatitis

N =

20A

llergic Eczema

N =

10

15%

25 %

30%

20%

10%

20%

50%

20%

Only w

ith 15 % there w

aslittle efficiency, w

ith the restof the p

opulation (85%

) thetreatm

ent was d

efinitelyeffective.

Initial deterioration followed by

slight improvem

ent with 20 %

and 70 % w

ithin the range ofefficiency.

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Efficien

cy with

"N" p

erson

s examin

ed (Tab

le 2)

© D

r. med

. Breier, C

ologne, Octob

er 1993

20%

20%40%

20%

10%

40%

30%

15%10%

5%

20%

55%

15%

10%

40%

35%

15%

10%

60%

30%

10%

Coxartthr.N

= 30

Lumb

algiaN

= 40

Sp

ondylarthr.

N =

40O

ccipital - N

euralgiaN

= 30

Migraine

N =

20

20% are so strongly

degenerated

and m

odified

in their anatomic structure,

that recuperation is

imp

ossible.

With 10%

recurrence overyears, also p

ostoperative w

ithp

ain and restricted

mob

ility.R

egarding the severity of the

disease success in sm

allgroup

s, but nevertheless

definite.

Often com

bined

with

lumbalgie and Ischiasneuralgia

and d

egenerative, effectthinkab

le over tendinous

structures and w

ithrem

arkable success.

Occip

ital-Neuralgia and

migraine w

ith definite therap

euticalsuccess.

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Efficien

cy with

"N" p

erson

s examin

ed (Tab

le 3)

© D

r. med

. Breier, C

ologne, Octob

er 1993

30%

40%

10%

10%

10%45%

25%

30%

60%

40%

10%

40%

20%

30%

15%

45%

20%

IschialgiaN

= 30

Cervical sp

ine syndrom

eN

= 40

Ankle joint d

istorsionN

= 5

AS

L Sp

eechN

=1

AS

L Sw

allowing

N =

130%

chronically recurrent,b

ut good success in sm

allgroup

s.

Hard

ly any success with the

increase of mob

ility, but a

reduction of p

ain andoed

emas.

With around

50% slight im

provem

ent of speech, b

ut notstab

le, better w

ith swallow

ing. the disease is in p

rogress, thep

atients very unstable.

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Efficien

cy with

"N" p

erson

s examin

ed (Tab

le 4)

© D

r. med

. Breier, C

ologne, Octob

er 1993

Extra pyramidal syndrome*

Cystitis N = 15

Pyelitis N = 5

Sinusitis N = 20

GB

S N

= 1

Dep

ressionsN

= 12

Phob

iaN

= 10

Disturb

ed sleep

N =

20

20%

80%

30%

30%

30%

40% 20% 10% 10% 20%

20%

30%

20%

20%

20%

30%40%

10%

20%

*EP

S: Ind

ifferent behavior caused

psychich d

isturbance.

With d

epressions instab

le patient structure, efficiency only in a sm

all group of 30 %

%relatively stab

le, otherwise short efficiency and

recurrent, similar to p

hobia.

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Traumatic laryngitisN

= 1

Bacterial laryg.

N =

5O

titis med

iaN

= 5

Angina

N =

2

10%

40%

20%

15%

15%

20%

20%

30%

15%

15%

15%

25%

20%20%

20%

30%

40%10%

20%

Otitis m

edia and

angina comp

arable form

and d

efiniteefficiency w

ithout recurrence.

Efficien

cy with

"N" p

erson

s examin

ed (Tab

le 5)

© D

r. med

. Breier, C

ologne, Octob

er 1993

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Efficien

cy with

"N" p

erson

s examin

ed (Tab

le 6)

© D

r. med

. Breier, C

ologne, Octob

er 1993

25%

15%

20%

15%

Chron. p

olyarthritisN

= 8

Chron. A

rthr.N

= 13

AV

K II b

N =

2C

HD

N =

5

10%

15%

30%

20%

10%

10%

10%

10%

30%

60%

40%

30%

20%

10%

20%

Strong d

egeneration of thefingers w

ith restrictedm

obility and

pain.

Ab

out ca. 40% w

ith small or

no effect. 35 % w

ithm

oderate effect, slightly

imp

roved m

obility and

reduced

pain. N

o recurrence.D

uration of efficiencyrelatively stab

le. 25% w

ithexellent and

stable effect.

No recurrence

up to end

of Nov. 93.

Often coronary insufficiency

with d

ecomp

ensated geriatric

heart; inspite d

efinite sym

ptom

atic imp

rovement

and red

uction of the dysp

noe.

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Efficien

cy with

"N" p

erson

s examin

ed (Tab

le 7)

© D

r. med

. Breier, C

ologne, Octob

er 1993

30%

20%

20%

30%

20%

25%10%

40%30%

Ulcus venosum

N =

5C

erebral circ. d

isturb.

N =

15D

epressions

N =

12P

hobia

N =

10D

isturbed

sleepN

= 20

30%

20%20%

30%

30%

25%

20%

20%

10%

30%

20%

20%

Chronic system

diseases

with rep

eated recurrence,

30% ind

ifferent, 20% slight

occusion of the ulcus but no

total healing, 50 % w

ithsatisfying closure, norecurrence.

Vascular degeneration, only

in 20 % of the cases slight

symp

tomatic im

provem

entp

ossible.

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Efficien

cy with

"N" p

erson

s examin

ed (Tab

le 8)

© D

r. med

. Breier, C

ologne, Octob

er 1993

20%

30%Gastritis

N =

20O

bstip

ationN

= 20

DiarrhoeN

= 4

Colitis ulzerosa

N =

12

20%

30%

20%

30%20%

30%

30%

20%

20%

30%10%

20%

20%

30%

20%

90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %

first reaction

RecuperationDeterioration

small success

Placebo

Efficien

cy with

"N" p

erson

s examin

ed (Tab

le 9)

© D

r. med

. Breier, C

ologne, Octob

er 1993

35%

30%

40%20%

20%

10%

40%

10%

30%

10%

Retinal circ. d

ist.N

= 8

Deg. of the m

aculaN

= 2

bronchial asthm

a

N =

20

Allgic asthm

aN

= 10

Allergic R

hinitisN

= 22

35%40%

30%

30%

30%

20%

30%

20%

20%

In 30% of the cxases

lasting imp

rovement of the

vision (eye charts, short-and

longsighted)

30% d

estruction of theresp

iratory passages,

degenerative, only slight

symp

tomatic im

provem

ent. 50%

with slight or good

imp

rovement also of the vital

capacity. 40%

with clear

symp

tomatic im

provem

entalso of the vital cap

acity.

A llergic rhinitis d

epend

s onallegies and

seasons. 20 %w

ithout clear effect. 30 %variab

le for the same reasons.

Rest of the p

opulation w

ithd

efinite success without

recurrence.